Correlation of total polyphenolic content with antioxidant and antibacterial activity of 24 extracts from Greek domestic Lamiaceae species

Lamiaceae family species are considered important because of their use in folk medicine, culinary and flavouring throughout the world. Their interesting bioactivities are attributed mainly to essential oils, polyphenols and terpenes. However, there are only few studies about polyphenolic extracts from Lamiaceae plants. Thus, 24 polyphenolic extracts from three Lamiaceae genera, Salvia, Mentha and Sideritis, collected in Greece were examined for antioxidant and antibacterial activity in correlation with their polyphenolic content. The results showed that the tested polyphenolic extracts had strong free radical scavenging activity against DPPH. and ABTS. radicals and protected from hydroxyl and peroxyl radical-induced DNA damage. Moreover, five extracts inhibited Staphylococcus aureus growth. Furthermore, the results showed that the total polyphenolic content is not correlated with the above activities, although this relation was different within each plant genus. This is the first study regarding the antioxidant and antibacterial activity of Salvia pomifera ssp. calycina. S. pomifera ssp. pomifera, Mentha microphylla and Sideritis raeseri ssp. attica species, and one of the few concerning protection from DNA damage and antibacterial activity of polyphenolic extracts from the rest of the tested species. (C) 2012 Elsevier Ltd. All rights reserved

In-Season Integrative Neuromuscular Strength Training Improves Performance of Early-Adolescent Soccer Athletes

Panagoulis, C, Chatzinikolaou, A, Avloniti, A, Leontsini, D, Deli, CK, Draganidis, D, Stampoulis, T, Oikonomou, T, Papanikolaou, K, Rafailakis, L, Kambas, A, Jamurtas, AZ, and Fatouros, IG. In-season integrative neuromuscular strength training improves performance of early-adolescent soccer athletes. J Strength Cond Res 34(2): 516-526, 2020-Although forms of integrative neuromuscular training (INT) are used extensively for injury prevention and treatment, no information exists about its effects on performance of adolescent athletes. We investigated the effects of an in-season INT intervention on performance of early-adolescent players using a 2-group, repeated-measures design. Twenty-eight early adolescents were randomly assigned to a control group (CG, participated only in soccer training, N = 14, 11.4 ± 0.57 years, Tanner stage 2.8 ± 0.6) or an experimental group (INT was added to conventional soccer training, N = 14, 11.2 ± 0.5 years, Tanner stage 2.6 ± 0.5). Integrative neuromuscular training (8 weeks, 3 sessions·wk) aimed to develop core strength, hamstrings eccentric strength, hip/knee musculature, and dynamic stability using body mass exercises, medicine balls, rocker boards, Bosu, stability balls, etc. Ball shooting speed, speed (10, 20-m), change of direction (COD), jumping performance, and strength were measured before and after training. A 2-way repeated-measures ANOVA was used to analyze data. Integrative neuromuscular training improved 10- and 20-m speed (2.52-2.13 and 3.61-3.39 seconds, respectively, p < 0.05), strength (40.1-44.4 kg, p < 0.05), jumping ability (squat jump: 16.3-17.9 cm; countermovement jump: 19.1-20.3 cm, p < 0.05), COD (18.0-17.3 seconds, p < 0.05), and shooting speed (73.8-79.0 km·h, p < 0.05). In the CG, soccer training caused an improvement of smaller magnitude in 10 m and shooting speed (p < 0.05), whereas COD and jumping performance remained unaffected while 20-m speed, COD, and strength deteriorated. These results indicate that an 8-week INT program may induce positive adaptations in performance of early-adolescent soccer players during in-season training, suggesting that INT may be an effective training intervention for this age group

Evolocumab and clinical outcomes in patients with cardiovascular disease

peer reviewedBACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. METHODS We conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving statin therapy. Patients were randomly assigned to receive evolocumab (either 140 mg every 2 weeks or 420 mg monthly) or matching placebo as subcutaneous injections. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. The key secondary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The median duration of follow-up was 2.2 years. RESULTS At 48 weeks, the least-squares mean percentage reduction in LDL cholesterol levels with evolocumab, as compared with placebo, was 59%, from a median baseline value of 92 mg per deciliter (2.4 mmol per liter) to 30 mg per deciliter (0.78 mmol per liter) (P<0.001). Relative to placebo, evolocumab treatment significantly reduced the risk of the primary end point (1344 patients [9.8%] vs. 1563 patients [11.3%]; hazard ratio, 0.85; 95% confidence interval [CI], 0.79 to 0.92; P<0.001) and the key secondary end point (816 [5.9%] vs. 1013 [7.4%]; hazard ratio, 0.80; 95% CI, 0.73 to 0.88; P<0.001). The results were consistent across key subgroups, including the subgroup of patients in the lowest quartile for baseline LDL cholesterol levels (median, 74 mg per deciliter [1.9 mmol per liter]). There was no significant difference between the study groups with regard to adverse events (including new-onset diabetes and neurocognitive events), with the exception of injection-site reactions, which were more common with evolocumab (2.1% vs. 1.6%). CONCLUSIONS In our trial, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events. These findings show that patients with atherosclerotic cardiovascular disease benefit from lowering of LDL cholesterol levels below current targets. © 2017 Massachusetts Medical Society

Evolocumab and clinical outcomes in patients with cardiovascular disease

BACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. METHODS We conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving statin therapy. Patients were randomly assigned to receive evolocumab (either 140 mg every 2 weeks or 420 mg monthly) or matching placebo as subcutaneous injections. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. The key secondary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The median duration of follow-up was 2.2 years. RESULTS At 48 weeks, the least-squares mean percentage reduction in LDL cholesterol levels with evolocumab, as compared with placebo, was 59%, from a median baseline value of 92 mg per deciliter (2.4 mmol per liter) to 30 mg per deciliter (0.78 mmol per liter) (P<0.001). Relative to placebo, evolocumab treatment significantly reduced the risk of the primary end point (1344 patients [9.8%] vs. 1563 patients [11.3%]; hazard ratio, 0.85; 95% confidence interval [CI], 0.79 to 0.92; P<0.001) and the key secondary end point (816 [5.9%] vs. 1013 [7.4%]; hazard ratio, 0.80; 95% CI, 0.73 to 0.88; P<0.001). The results were consistent across key subgroups, including the subgroup of patients in the lowest quartile for baseline LDL cholesterol levels (median, 74 mg per deciliter [1.9 mmol per liter]). There was no significant difference between the study groups with regard to adverse events (including new-onset diabetes and neurocognitive events), with the exception of injection-site reactions, which were more common with evolocumab (2.1% vs. 1.6%). CONCLUSIONS In our trial, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events. These findings show that patients with atherosclerotic cardiovascular disease benefit from lowering of LDL cholesterol levels below current targets